These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 100809)

  • 1. Psychopharmacological studies on (--)-nuciferine and its Hofmann degradation product atherosperminine.
    Bhattacharya SK; Bose R; Ghosh P; Tripathi VJ; Ray AB; Dasgupta B
    Psychopharmacology (Berl); 1978 Sep; 59(1):29-33. PubMed ID: 100809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
    Khisti RT; Deshpande LS; Chopde CT
    Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central action of glaucine in rodents.
    Jagiełło-Wójtowicz E; Kleinrok Z; Jusiak L; Matuszek B; Daniłoś J; Chodakowska A
    Acta Pol Pharm; 1994; 51(2):179-84. PubMed ID: 7863789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
    Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
    Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential attenuation of some effects of haloperidol in rats given scopolamine.
    Setler P; Sarau H; McKenzie G
    Eur J Pharmacol; 1976 Sep; 39(1):117-26. PubMed ID: 986946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRL 20596, a novel anilide with central dopamine antagonist activity.
    Campbell W; Clark MS; Mitchell PJ; Needham PL; Semple JM
    Psychopharmacology (Berl); 1986; 89(2):208-15. PubMed ID: 3088638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic-like, anticonvulsant and antinociceptive effects of aporphine alkaloids: bulbocapnine, corytuberine, boldine and glaucine.
    Zetler G
    Arch Int Pharmacodyn Ther; 1988; 296():255-81. PubMed ID: 2907279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacological profile of mesterolone.
    Baran L; Przegaliński E
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug.
    Voith K; Herr F
    Psychopharmacologia; 1975 Apr; 42(1):11-20. PubMed ID: 1171496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.
    Arnt J
    Acta Pharmacol Toxicol (Copenh); 1982 Oct; 51(4):321-9. PubMed ID: 6129770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug.
    Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M
    Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of muscarinic receptor agonists on animal models of psychosis.
    Karan RS; Ravishankar P; Pandhi P
    Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):169-72. PubMed ID: 10893700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of substituted gamma-butyrolactones. I. The effects on the central nervous system.
    Sieroslawska J; Hano J; Sypniewska M; Czarnecki R; Chojnacka-Wójcik E; Harasiewicz A
    Pol J Pharmacol Pharm; 1973; 25(1):1-16. PubMed ID: 4798097
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of angiotensin on the central action of dopamine.
    Braszko J; Wiśniewski K
    Pol J Pharmacol Pharm; 1976; 28(6):667-72. PubMed ID: 1034924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation between behavioral effects of (-)-N-(2-chloroethyl)-norapomorphine and D2 dopamine receptor-like activity.
    Helmeste DM
    Eur J Pharmacol; 1983 Nov; 95(3-4):277-81. PubMed ID: 6317413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphetamine-haloperidol interactions in rat striatum: failure to correlate behavioral effects with dopaminergic and cholinergic dynamics.
    Kuczenski R; Schmidt D; Leith N
    Brain Res; 1977 Apr; 126(1):117-29. PubMed ID: 558038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is dopamine antagonism a requisite of neuroleptic activity?
    Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.